Currax Pharmaceuticals LLC
April 1, 2026
Press Releases
CONTRAVE®
March 25, 2026
CONTRAVE Given the Highest Recommendation by Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults with Overweight or Obesity
See moreCONTRAVE®
November 4, 2025
Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
See moreCONTRAVE®
October 28, 2025
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
See moreCURRAX PHARMACEUTICALS LLC
October 23, 2025
Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
See moreCURRAX PHARMACEUTICALS
August 5, 2025
Currax Announces National Expansion of “Cravings Don’t Own Me” CTV Commercial, Along with Launch of New “Real Patients, Real Results” DTC Campaign
See moreContrave®
July 15, 2025
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
See moreCONTRAVE®/MYSIMBA
March 20, 2025
Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site
See moreCONTRAVE®/MYSIMBA®
March 11, 2025